RoesLuger flags 3–11% HPV‑negative cancers

Cervical cancer screening is moving toward HPV-first testing. That makes sense — persistent high-risk HPV drives nearly all cervical cancers, and HPV-based screening is generally better than cytology alone at preventing cancer over time. But the gap has never fully disappeared. A small slice of cancers and high-grade lesions still come back HPV-negative, either because the test missed them or because the tumor is one of the rarer cervical cancers that really is HPV-independent. That is the issue RoesLuger was pointing at — and it lands at a moment when U.S. screening guidance is putting even more weight on HPV testing. ### What is the actual claim here? The headline number is not that HPV tests “don’t work.” It is that HPV-negative cervical cancer is a real, repeatedly described category in the literature. One major review puts the share at about 5.5–11% of cervical cancers, while another recent review says HPV-negative cervical cancer remains consistently reported worldwide. That bucket mixes together two different things — truly HPV-independent tumors and false-negative test results. (thelancet.com) ### Why would a cervical cancer test HPV-negative? Basically, there are two paths. One is biology. Some cervical adenocarcinomas appear to arise without the usual HPV-driven pathway. The other is measurement error. Reviews list several reasons a cancer can look HPV-negative even when HPV played a role: misclassified tumor type, low viral load, loss of the viral target region, non-high-risk HPV types, sampling problems, or limits of the assay itself. So “HPV-negative” does not always mean “HPV had nothing to do with it.” (frontiersin.org) ### Does that mean Pap tests still matter? Yes — but in a specific way. Pap cytology does not look for the virus. It looks for abnormal cervical cells. That means it can sometimes flag precancer or cancer when an HPV test is negative at that moment. CDC still describes the Pap test as a way to find precancers before they turn into cancer, and U.S. screening frameworks still keep cytology in the menu even as HPV testing takes the lead. (frontiersin.org) ### So why is screening still shifting to HPV-first? Because at the population level, HPV-based screening performs better. WHO recommends HPV DNA testing as the preferred screening method, and long-term trial evidence has favored primary HPV screening over cytology for preventing cervical cancer. The catch is that “better overall” does not mean “perfect in every individual case.” Screening policy is built around the biggest net benefit, then tries to manage the misses with follow-up rules and triage. (cdc.gov) ### What changed recently in the U.S.? The direction of travel got clearer. ACOG released updated guidance on April 23, 2026, endorsing Women’s Preventive Services Initiative recommendations and adding patient-collected high-risk HPV testing as an option for average-risk patients ages 30–65 every 3 years. ACS updated its guideline in December 2025 and continues to prefer primary HPV testing every 5 years for average-risk people ages 25–65. (who.int) ### Where does the debate sit now? It is less “HPV versus Pap” than “how much backup do you want around HPV?” Some clinicians are comfortable with HPV-primary strategies because they win on overall sensitivity and scalability. Others point to the HPV-negative edge cases and argue for co-testing, reflex cytology, or repeat testing when symptoms or other findings do not fit the lab result. That tension gets sharper as self-collected HPV testing expands. (acog.org) ### What’s the bottom line? RoesLuger’s point is directionally sound. A small but real share of cervical cancers test HPV-negative in published reviews, and that is one reason Pap cytology has not become irrelevant. But it does not overturn the broader case for HPV-first screening. It just means the edge cases matter — especially when a negative HPV result clashes with symptoms, cytology, or clinical suspicion. (frontiersin.org) (acog.org)